PEDRO PIEDRA to Antibodies, Monoclonal
This is a "connection" page, showing publications PEDRO PIEDRA has written about Antibodies, Monoclonal.
Connection Strength
0.190
-
Comparison of Palivizumab-Like Antibody Binding to Different Conformations of the RSV F Protein in RSV-Infected Adult Hematopoietic Cell Transplant Recipients. J Infect Dis. 2018 03 28; 217(8):1247-1256.
Score: 0.091
-
Comparison of the inhibition of human metapneumovirus and respiratory syncytial virus by ribavirin and immune serum globulin in vitro. Antiviral Res. 2003 Sep; 60(1):51-9.
Score: 0.033
-
The respiratory syncytial virus vaccine landscape: lessons from the graveyard and promising candidates. Lancet Infect Dis. 2018 10; 18(10):e295-e311.
Score: 0.023
-
Clinical Endpoints for Respiratory Syncytial Virus Prophylaxis Trials in Infants and Children in High-income and Middle-income Countries. Pediatr Infect Dis J. 2015 Oct; 34(10):1086-92.
Score: 0.019
-
Glycan variants of a respiratory syncytial virus antibody with enhanced effector function and in vivo efficacy. Proc Natl Acad Sci U S A. 2014 Apr 22; 111(16):5992-7.
Score: 0.017
-
Prevention and treatment of respiratory syncytial virus and parainfluenza viruses in immunocompromised patients. Am J Med. 1997 Mar 17; 102(3A):61-70; discussion 75-6.
Score: 0.005